NCT05834426View on ClinicalTrials.gov

Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Lymphoma, B-CellNeoplasmsCancerHigh-grade B-cell LymphomaDiffuse Large B Cell LymphomaNon Hodgkin LymphomaMetabolomics
Interventions
DIAGNOSTIC_TEST

Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)

For metabolomic analysis, different portions of the blood (plasma and lymphocytes) will be subjected to metabolite extraction by the extraction method defined by Glasgow Polyomics. With protein precipitation, 200 microliters (uL) of the fluid with the metabolites is transferred to a new microtube and must be maintained at -80 °C until the time of metabolomic analysis.

Trial Locations (1)

090505

Instituto Oncológico Nacional Dr. Juan Tanca Marengo, Guayaquil

All Listed Sponsors
lead

Sociedad de Lucha Contra el Cáncer del Ecuador

OTHER

NCT05834426 - Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers | Biotech Hunter | Biotech Hunter